Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Rhea-AI Summary

Syros Pharmaceuticals (SYRS) announced a live conference call and webcast for May 16, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and provide corporate updates. Investors can access the call via telephone (866-595-4538 domestic) or through the company's website. Syros focuses on developing small molecule medicines that manipulate gene expression and has a pipeline featuring tamibarotene for myelodysplastic syndrome and leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors and blood cancers.

Positive

• Pipeline includes innovative therapies like tamibarotene, SY-2101, and SY-5609.
• Robust clinical-stage pipeline targeting various cancers indicates potential for future revenue growth.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide a corporate update.

To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international) and refer to conference ID 4664097. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005028/en/

Media:

Courtney Solberg

Syros Pharmaceuticals

917-698-9253

csolberg@syros.com

Investor:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When will Syros Pharmaceuticals announce its Q1 2022 financial results?

Syros Pharmaceuticals will announce its Q1 2022 financial results on May 16, 2022.

What is the stock symbol for Syros Pharmaceuticals?

The stock symbol for Syros Pharmaceuticals is SYRS.

How can I access the Syros Pharmaceuticals conference call?

You can access the Syros Pharmaceuticals conference call by dialing (866) 595-4538 for domestic calls or (636) 812-6496 for international calls.

What therapies are in Syros Pharmaceuticals' pipeline?

Syros Pharmaceuticals has a pipeline that includes tamibarotene for myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for various solid tumors.